Literature DB >> 29778854

Proposed Stages of Myocardial Phenotype Development in Fabry Disease.

Sabrina Nordin1, Rebecca Kozor2, Katia Medina-Menacho1, Amna Abdel-Gadir1, Shanat Baig3, Daniel M Sado4, Ilaria Lobascio5, Elaine Murphy6, Robin H Lachmann6, Atul Mehta7, Nicola C Edwards3, Uma Ramaswami7, Richard P Steeds3, Derralynn Hughes7, James C Moon8.   

Abstract

OBJECTIVES: This study sought to explore the Fabry myocardium in relation to storage, age, sex, structure, function, electrocardiogram changes, blood biomarkers, and inflammation/fibrosis.
BACKGROUND: Fabry disease (FD) is a rare, x-linked lysosomal storage disorder. Mortality is mainly cardiovascular with men exhibiting cardiac symptoms earlier than women. By cardiovascular magnetic resonance, native T1 is low in FD because of sphingolipid accumulation.
METHODS: A prospective, observational study of 182 FD (167 adults, 15 children; mean age 42 ± 17 years, 37% male) who underwent cardiovascular magnetic resonance including native T1, late gadolinium enhancement (LGE), and extracellular volume fraction, 12-lead electrocardiogram, and blood biomarkers (troponin and N-terminal pro-brain natriuretic peptide).
RESULTS: In children, T1 was never below the normal range, but was lower with age (9 ms/year, r = -0.78 children; r = -0.41 whole cohort; both p < 0.001). Over the whole cohort, the T1 reduction with age was greater and more marked in men (men: -1.9 ms/year, r = -0.51, p < 0.001; women: -1.4 ms/year, r = -0.47 women, p < 0.001). Left ventricular hypertrophy (LVH), LGE, and electrocardiogram abnormalities occur earlier in men. Once LVH occurs, T1 demonstrates major sex dimorphism: with increasing LVH in women, T1 and LVH become uncorrelated (r = -0.239, p = 0.196) but in men, the correlation reverses and T1 increases (toward normal) with LVH (r = 0.631, p < 0.001), a U-shaped relationship of T1 to indexed left ventricular mass in men.
CONCLUSIONS: These data suggest that myocyte storage starts in childhood and accumulates faster in men before triggering 2 processes: a sex-independent scar/inflammation regional response (LGE) and, in men, apparent myocyte hypertrophy diluting the T1 lowering of sphingolipid.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fabry disease; gender; native T1; phenotype

Mesh:

Substances:

Year:  2018        PMID: 29778854     DOI: 10.1016/j.jcmg.2018.03.020

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  28 in total

Review 1.  Narrative review on Morbus Fabry: diagnosis and management of cardiac manifestations.

Authors:  Aleš Linhart; Tomáš Paleček
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

2.  Coronary microvascular disease in hypertrophic and infiltrative cardiomyopathies.

Authors:  Andreas A Giannopoulos; Ronny R Buechel; Philipp A Kaufmann
Journal:  J Nucl Cardiol       Date:  2022-08-01       Impact factor: 3.872

Review 3.  Beyond Sarcomeric Hypertrophic Cardiomyopathy: How to Diagnose and Manage Phenocopies.

Authors:  Maurizio Pieroni; Michele Ciabatti; Elisa Saletti; Valentina Tavanti; Pasquale Santangeli; Lucia Martinese; Francesco Liistro; Iacopo Olivotto; Leonardo Bolognese
Journal:  Curr Cardiol Rep       Date:  2022-09-02       Impact factor: 3.955

4.  The role of native T1 values on the evaluation of cardiac manifestation in Japanese Fabry disease patients.

Authors:  Ikuko Anan; Toru Sakuma; Eiko Fukuro; Satoshi Morimoto; Ayumi Nojiri; Makoto Kawai; Ken Sakurai; Masahisa Kobayashi; Hiroshi Kobayashi; Hiroyuki Ida; Toya Ohashi; Michihiro Yoshimura; Yoshikatsu Eto; Kenichi Hongo
Journal:  Mol Genet Metab Rep       Date:  2022-03-16

Review 5.  2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease.

Authors:  Chung-Lieh Hung; Yen-Wen Wu; Chih-Chan Lin; Chih-Hung Lai; Jimmy Jyh-Ming Juang; Ting-Hsing Chao; Ling Kuo; Kuo-Tzu Sung; Chao-Yung Wang; Chun-Li Wang; Chun-Yuan Chu; Wen-Chung Yu; Charles Jia-Yin Hou
Journal:  Acta Cardiol Sin       Date:  2021-07       Impact factor: 2.672

6.  Quantitative Myocardial Perfusion in Fabry Disease.

Authors:  Kristopher D Knott; Joao B Augusto; Sabrina Nordin; Rebecca Kozor; Claudia Camaioni; Hui Xue; Rebecca K Hughes; Charlotte Manisty; Louise A E Brown; Peter Kellman; Uma Ramaswami; Derralyn Hughes; Sven Plein; James C Moon
Journal:  Circ Cardiovasc Imaging       Date:  2019-07-04       Impact factor: 7.792

7.  Quantification of myocardial deformation in patients with Fabry disease by cardiovascular magnetic resonance feature tracking imaging.

Authors:  Lei Zhao; Chen Zhang; Jie Tian; Madiha Saiedi; Chenyao Ma; Ning Li; Fang Fang; Xiaohai Ma; Joseph Selvanayagam
Journal:  Cardiovasc Diagn Ther       Date:  2021-02

Review 8.  Fabry Disease and the Heart: A Comprehensive Review.

Authors:  Olga Azevedo; Filipa Cordeiro; Miguel Fernandes Gago; Gabriel Miltenberger-Miltenyi; Catarina Ferreira; Nuno Sousa; Damião Cunha
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

Review 9.  The spectrum of myocarditis: from pathology to the clinics.

Authors:  Ornella Leone; Maurizio Pieroni; Claudio Rapezzi; Iacopo Olivotto
Journal:  Virchows Arch       Date:  2019-07-11       Impact factor: 4.535

10.  The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage.

Authors:  João B Augusto; Nicolas Johner; Dipen Shah; Sabrina Nordin; Kristopher D Knott; Stefania Rosmini; Clement Lau; Mashael Alfarih; Rebecca Hughes; Andreas Seraphim; Ravi Vijapurapu; Anish Bhuva; Linda Lin; Natalia Ojrzyńska; Tarekegn Geberhiwot; Gabriella Captur; Uma Ramaswami; Richard P Steeds; Rebecca Kozor; Derralynn Hughes; James C Moon; Mehdi Namdar
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-06-22       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.